Back to Acceleration Radar
NVSTEnvista Holdings Corp
Health Care · Medical/Dental Instruments · Mid
$23.60−1.54%
As of 23 Oct 2026Mkt cap $4.4B
Stage 13
AVOID
Fundamentals
21.2/75
Technical
5.0/15
Independent
26.2/90
GCAE viewstructural technical damage is a hard non-actionable condition
Price
- 1M
- −2.0%
- 3M
- −11.4%
- 6M
- −11.9%
- 1Y
- +19.0%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 40.7xHist median 84.4x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 16.1x
- FCF yield
- 6.2%
Quality
- ROIC
- —
- Operating margin
- 1.2%
- FCF margin
- 8.5%
- Current ratio
- 2.4x
Growth
- Revenue growth
- +8.3%Latest FY YoY
- Revenue CAGR
- +2.0%
- EPS CAGR
- −38.2%
- FCF CAGR
- −6.9%
Capital
- Share-count trend
- +0.7%3Y annualised
- Net debt
- $247M0.9x OCF
Annual trend
- CAGR 2021–2025
- +2.0%
- Latest · 2025
- $3B
- YoY
- +8.3%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
structural technical damage is a hard non-actionable condition
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-04
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- damaged
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded